Výsledky vyhledávání

Akademický článek

The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.

Autor: Robert J Moots, Ricardo M Xavier, Chi Chiu Mok, Mahboob U Rahman, Wen-Chan Tsai, Mustafa H Al-Maini, Karel Pavelka, Ehab Mahgoub, Sameer Kotak, Joan Korth-Bradley, Ron Pedersen, Linda Mele, Qi Shen, Bonnie Vlahos

Publikováno v: PLoS ONE, Vol 12, Iss 4, p e0175207 (2017)

OBJECTIVE:To assess the incidence of anti-drug antibodies (ADA) in patients with rheumatoid arthritis (RA) treated with the TNF inhibitors etanercept (ETN), adalimumab (ADL), or infliximab (IFX), and determine the potential relationship with trough d

Externí odkaz: https://doaj.org/article/6af16e2d555b4839b6545a44c5ff9ea2

Zobrazit plný text záznamu

Long-term safety and tolerability of oral tofacitinib in patients with Crohn’s disease: results from a phase 2, open-label, 48-week extension study

Autor: Julián Panés, Wenjin Wang, Michele Moscariello, Linda Mele, Eric S. Maller, Geert R. D'Haens, Gary Chan, Wojciech Niezychowski, Peter D.R. Higgins, Chinyu Su

Publikováno v: Alimentary pharmacology & therapeutics, 49(3), 265-276. Wiley-Blackwell
Alimentary Pharmacology & Therapeutics

Summary Background Tofacitinib is an oral, small molecule Janus kinase inhibitor that is being investigated for inflammatory bowel disease. Aims This 48‐week open‐label extension study primarily investigated long‐term safety of tofacitinib 5 an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90021cf69f22c1c3a6bee60747bf9c39
https://pure.amc.nl/en/publications/longterm-safety-and-tolerability-of-oral-tofacitinib-in-patients-with-crohns-disease-results-from-a-phase-2-openlabel-48week-extension-study(15cd38f4-44a9-497d-b421-943769856dfe).html

Zobrazit plný text záznamu

Two-Year Safety and Efficacy Experience in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis Treated with Etanercept and Conventional Disease-Modifying Anti-rheumatic Drugs in the Latin American Region

Autor: Renato Guzmán, Daniel A. Machado, Ricardo Machado Xavier, Bonnie Vlahos, Qi Shen, Sameer Kotak, Jesus A. Simon, Linda Mele, Ronald Pedersen

Publikováno v: The Open Rheumatology Journal
Repositório Institucional da UFRGS
Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS

Background:Although long-term data are available from biologic studies in North American/European populations with rheumatoid arthritis (RA), long-term findings in Latin American RA populations are limited.Objective:To examine long-term safety/effica

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0030d9025decb9d239d1c9321f069ea2
http://europepmc.org/articles/PMC4780479

Zobrazit plný text záznamu

Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder

Autor: Matthieu Boucher, Ru-fong Cheng, Linda Mele, Karen A. Tourian, Eunhee Hwang, Lucy Abraham, Anita H. Clayton, Susan G. Kornstein

Publikováno v: International Clinical Psychopharmacology. 30:307-315

The primary objective of this post-hoc analysis was to evaluate the effect of short-term treatment with desvenlafaxine versus placebo on sexual dysfunction (SD), assessed from Arizona Sexual Experiences Scale scores, in adult outpatients with major d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f569f1765fb240b141f3b93b9a7f2e2
https://doi.org/10.1097/yic.0000000000000094

Zobrazit plný text záznamu

Autor: Joan M. Korth-Bradley, Sameer Kotak, Mustafa Al-Maini, Bonnie Vlahos, Qi Shen, Ricardo Machado Xavier, Linda Mele, Ron Pedersen, Robert J. Moots, Ehab Mahgoub, Wen-Chan Tsai, Mahboob Rahman, Chi Chiu Mok, Karel Pavelka

Publikováno v: PLoS ONE, Vol 12, Iss 4, p e0175207 (2017)
PLoS ONE
PLOS ONE

Objective To assess the incidence of anti-drug antibodies (ADA) in patients with rheumatoid arthritis (RA) treated with the TNF inhibitors etanercept (ETN), adalimumab (ADL), or infliximab (IFX), and determine the potential relationship with trough d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e565555ad08726f4e9a491b3ad379fcc
http://europepmc.org/articles/PMC5407581?pdf=render

Zobrazit plný text záznamu

Akademický článek

Backtalk: Readers Express Ire, Approval

Autor: Daher, Judy, Seniuk, Sophie, Dickinson, Gail K., Gilmore, Hattie, Ginsberg, Robert A., Minus, Vivian H., Johnson, Linda Mele

Publikováno v: The Phi Delta Kappan, 1991 Apr 01. 72(8), 644-648.

Externí odkaz: https://www.jstor.org/stable/20404490

Zobrazit plný text záznamu

Long-Term Safety and Tolerability of Oral Tofacitinib in Patients with Crohn’s Disease: Results from a Phase 2 Open-Label 48-Week Extension Study

Autor: Gary Chan, Julián Panés, Linda Mele, Wojciech Niezychowski, Geert R. D'Haens, Wenjin Wang, Michele Moscariello, Chinyu Su, Peter D.R. Higgins, Eric S. Maller

Publikováno v: Gastroenterology. 152:S599

Background: Tofacitinib is an oral, small molecule Janus kinase inhibitor that is being investigated for inflammatory bowel disease. Aims: This 48-week open-label extension study primarily investigated long-term safety of tofacitinib 5 and 10 mg b.d.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1b9c65e0ebcc37d8c525bbfcc3622c14
https://doi.org/10.1016/s0016-5085(17)32141-8

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání